CareDx, Inc. (NASDAQ: CDNA)

CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The company delivers solutions that empower clinicians and improve patient outcomes. Its integrated portfolio includes noninvasive molecular testing for heart kidney and lung transplants laboratory products digital health technologies and patient support services before and after transplant. Headquartered in Brisbane California with additional operations in Omaha Nebraska and Stockholm Sweden CareDx operates as a single reportable segment. The firm was incorporated in December 1998 and has undergone several name changes before becoming CareDx in March 2014. As of the end of 2025 the company employed approximately seven hundred sixty five people across research development manufacturing sales and administrative functions. CareDx’s mission centers on delivering actionable biological information that helps clinicians make informed decisions about immunosuppression therapy and graft surveillance.

CareDx generates revenue primarily from its testing services laboratory products and patient and digital solutions. Testing services include AlloSure Kidney AlloMap Heart AlloSure Heart HeartCare and AlloSure Lung which are reimbursed by Medicare private payers and Medicaid. The AlloSure Kidney test measures donor derived cell free DNA to detect early signs of kidney allograft injury and rejection. AlloMap Heart uses gene expression profiling to assess the probability of moderate to severe acute cellular rejection in heart transplant recipients. HeartCare combines AlloMap Heart and AlloSure Heart to provide a combined assessment of immune activation and graft injury. Laboratory products consist of HLA typing kits such as QTYPE Olerup SSP SBT and next generation sequencing based offerings like AlloSeq Tx AlloSeq HCT and AlloSeq cfDNA sold to hospitals and reference laboratories. QTYPE provides rapid human leukocyte antigen typing using polymerase chain reaction technology for deceased donor workflows. Olerup SSP SBT kits support low to high resolution HLA sequencing for transplant matching. AlloSeq Tx delivers high resolution HLA typing via hybrid capture sequencing covering additional non HLA genes relevant to transplant outcomes. AlloSeq HCT measures chimerism in stem cell transplant recipients to monitor engraftment and detect potential relapse. AlloSeq cfDNA quantifies donor derived cell free DNA in blood for surveillance across multiple organ types. Patient and digital solutions comprise workflow software such as Ottr Organ and Ottr Cellular referral management tools like TxAccess quality reporting platforms like XynQAPI medication adherence programs like MedActionPlan and the CareDx pharmacy service. Ottr Organ and Ottr Cellular integrate with electronic medical records to streamline transplant waitlist management and post transplant care coordination. TxAccess enables nephrologists and dialysis centers to submit electronic referrals to transplant programs and track patient progress through the waitlist. XynQAPI simplifies quality metric tracking and reporting to the Scientific Registry of Transplant Recipients. MedActionPlan offers personalized medication management tools to improve adherence and reduce graft loss risk. The CareDx pharmacy provides specialized medication dispensing counseling and insurance navigation for transplant patients. Revenue is derived from test fees product sales and subscription or service fees for digital platforms.

CareDx holds a leading position in the transplant diagnostics market as the premier provider of genomics based information for transplant recipients. The company differentiates itself through an integrated go to market model that targets a concentrated network of transplant centers and offers a broad portfolio of solutions that can be cross sold within the same institution. This approach reduces customer acquisition costs and increases utilization of its tests. Competitors in the molecular diagnostics space include Natera Eurofins Transplant Genomics Devyser and Insight Molecular Diagnostics. In the HLA typing arena the firm faces competition from Thermo Fisher through its One Lambda business as well as from Omixon GenDx BAG Qiagen and Immucor. For digital health solutions rivals include Phoenix the Epic transplant application TREX and MedSleuth. CareDx’s competitive advantages stem from its strong clinical validation data robust reimbursement relationships with Medicare and private payers its proprietary technology platform and its deep expertise in transplant immunology and workflow optimization. The firm has secured favorable coverage decisions for its major tests from Medicare Administrative Contractors and numerous private payer policies. Its ability to bundle multiple assays into a single patient encounter enhances convenience for clinicians and encourages broader adoption. Continuous investment in research and development supports a pipeline of next generation assays that address unmet needs in transplant surveillance and adjacent therapeutic areas. These factors together create a barrier to entry for new entrants seeking to replicate CareDx’s integrated service model.

CareDx serves transplant centers hospitals laboratories and patients across the United States and Europe. Its software platforms are used in more than 170 transplant centers in the U. S. The company’s testing products are ordered by clinicians managing heart kidney and lung transplant recipients while its laboratory kits are utilized by histocompatibility and immunogenetics laboratories for donor recipient matching and post transplant surveillance. Patient facing services such as the pharmacy and medication adherence programs support individuals undergoing transplantation and their caregivers. Although specific customer names are not disclosed in the filing the base includes academic medical centers community hospitals and specialty transplant programs. Geographically the majority of revenue is generated in the United States with a growing presence in European markets particularly Sweden and other Nordic countries. The company’s laboratory in Brisbane California processes approximately two hundred thousand tests annually supporting a large volume of transplant surveillance. Its manufacturing site in Stockholm Sweden produces HLA typing kits and next generation sequencing based products for distribution to global customers. By focusing on a defined customer group of transplant providers CareDx builds long term relationships that facilitate repeat business and upsell opportunities.